ASX - By Stock
|
ACW |
Re:
Ann: ACW raises an addtional $3.55m under a Shortfall Placement
|
|
Ricksanchezc137
|
8 |
3.5K |
2 |
10/02/21 |
10/02/21 |
ASX - By Stock
|
8
|
3.5K
|
2
|
|
ASX - By Stock
|
ACW |
Re:
Ann: Resignation of Dr Bill Ketelbey as Chief Executive Officer
|
|
Ricksanchezc137
|
164 |
56K |
2 |
08/02/21 |
08/02/21 |
ASX - By Stock
|
164
|
56K
|
2
|
|
ASX - By Stock
|
ACW |
Re:
Ann: Resignation of Dr Bill Ketelbey as Chief Executive Officer
|
|
Ricksanchezc137
|
164 |
56K |
5 |
08/02/21 |
08/02/21 |
ASX - By Stock
|
164
|
56K
|
5
|
|
ASX - By Stock
|
ACW |
Re:
Ann: Resignation of Dr Bill Ketelbey as Chief Executive Officer
|
|
Ricksanchezc137
|
164 |
56K |
3 |
08/02/21 |
08/02/21 |
ASX - By Stock
|
164
|
56K
|
3
|
|
ASX - By Stock
|
ACW |
Re:
SECOND VOUCHER
|
|
Ricksanchezc137
|
12 |
3.4K |
1 |
05/02/21 |
05/02/21 |
ASX - By Stock
|
12
|
3.4K
|
1
|
|
ASX - By Stock
|
ACW |
Re:
SECOND VOUCHER
|
|
Ricksanchezc137
|
12 |
3.4K |
9 |
05/02/21 |
05/02/21 |
ASX - By Stock
|
12
|
3.4K
|
9
|
|
ASX - By Stock
|
ACW |
Re:
Ann: Pause in Trading
|
|
Ricksanchezc137
|
11 |
2.6K |
3 |
05/02/21 |
05/02/21 |
ASX - By Stock
|
11
|
2.6K
|
3
|
|
ASX - By Stock
|
ACW |
Re:
Ann: Review of 2020 and outlook
|
|
Ricksanchezc137
|
59 |
21K |
4 |
25/01/21 |
25/01/21 |
ASX - By Stock
|
59
|
21K
|
4
|
|
ASX - By Stock
|
ACW |
Re:
Reducing cortisol as a cosmetic skin improver ?
|
|
Ricksanchezc137
|
4 |
1.2K |
0 |
16/11/20 |
16/11/20 |
ASX - By Stock
|
4
|
1.2K
|
0
|
|
ASX - By Stock
|
ACW |
Re:
Reducing cortisol as a cosmetic skin improver ?
|
|
Ricksanchezc137
|
4 |
1.2K |
4 |
14/11/20 |
14/11/20 |
ASX - By Stock
|
4
|
1.2K
|
4
|
|
ASX - By Stock
|
ACW |
Re:
Ann: Completion of Entitlement Offer
|
|
Ricksanchezc137
|
36 |
9.1K |
0 |
13/11/20 |
13/11/20 |
ASX - By Stock
|
36
|
9.1K
|
0
|
|
ASX - By Stock
|
ACW |
Re:
Ann: Completion of Entitlement Offer
|
|
Ricksanchezc137
|
36 |
9.1K |
2 |
13/11/20 |
13/11/20 |
ASX - By Stock
|
36
|
9.1K
|
2
|
|
ASX - By Stock
|
ACW |
Re:
Ann: Completion of Entitlement Offer
|
|
Ricksanchezc137
|
36 |
9.1K |
3 |
13/11/20 |
13/11/20 |
ASX - By Stock
|
36
|
9.1K
|
3
|
|
ASX - By Stock
|
ACW |
Re:
Ann: Completion of Entitlement Offer
|
|
Ricksanchezc137
|
36 |
9.1K |
2 |
13/11/20 |
13/11/20 |
ASX - By Stock
|
36
|
9.1K
|
2
|
|
ASX - By Stock
|
ACW |
Re:
Ann: Completion of Entitlement Offer
|
|
Ricksanchezc137
|
36 |
9.1K |
3 |
13/11/20 |
13/11/20 |
ASX - By Stock
|
36
|
9.1K
|
3
|
|
ASX - By Stock
|
ACW |
Re:
Ann: Completion of Entitlement Offer
|
|
Ricksanchezc137
|
36 |
9.1K |
7 |
13/11/20 |
13/11/20 |
ASX - By Stock
|
36
|
9.1K
|
7
|
|
ASX - By Stock
|
ACW |
Re:
CEO Interview
|
|
Ricksanchezc137
|
14 |
2.2K |
3 |
03/11/20 |
03/11/20 |
ASX - By Stock
|
14
|
2.2K
|
3
|
|
ASX - By Stock
|
ACW |
Re:
CEO Interview
|
|
Ricksanchezc137
|
14 |
2.2K |
2 |
02/11/20 |
02/11/20 |
ASX - By Stock
|
14
|
2.2K
|
2
|
|
ASX - By Stock
|
ACW |
Re:
CEO Interview
|
|
Ricksanchezc137
|
14 |
2.2K |
5 |
02/11/20 |
02/11/20 |
ASX - By Stock
|
14
|
2.2K
|
5
|
|
ASX - By Stock
|
ACW |
Re:
Ann: Offer Booklet
|
|
Ricksanchezc137
|
16 |
3.6K |
1 |
23/10/20 |
23/10/20 |
ASX - By Stock
|
16
|
3.6K
|
1
|
|
ASX - By Stock
|
ACW |
Re:
Ann: Actinogen Presentation & Planned Conference Call
|
|
Ricksanchezc137
|
31 |
5.5K |
1 |
19/10/20 |
19/10/20 |
ASX - By Stock
|
31
|
5.5K
|
1
|
|
ASX - By Stock
|
ACW |
Re:
Ann: Actinogen Presentation & Planned Conference Call
|
|
Ricksanchezc137
|
31 |
5.5K |
0 |
19/10/20 |
19/10/20 |
ASX - By Stock
|
31
|
5.5K
|
0
|
|
ASX - By Stock
|
ACW |
Re:
Ann: Letter to Optionholders re Non-Renounceable Rights Issue
|
|
Ricksanchezc137
|
4 |
1.5K |
2 |
16/10/20 |
16/10/20 |
ASX - By Stock
|
4
|
1.5K
|
2
|
|
ASX - By Stock
|
ACW |
Re:
Ann: Trading Halt
|
|
Ricksanchezc137
|
55 |
11K |
5 |
13/10/20 |
13/10/20 |
ASX - By Stock
|
55
|
11K
|
5
|
|
ASX - By Stock
|
ACW |
Re:
Ann: Trading Halt
|
|
Ricksanchezc137
|
55 |
11K |
2 |
13/10/20 |
13/10/20 |
ASX - By Stock
|
55
|
11K
|
2
|
|
ASX - By Stock
|
ACW |
Re:
Ann: Trading Halt
|
|
Ricksanchezc137
|
55 |
11K |
4 |
13/10/20 |
13/10/20 |
ASX - By Stock
|
55
|
11K
|
4
|
|
ASX - By Stock
|
ACW |
Re:
Ann: Trading Halt
|
|
Ricksanchezc137
|
55 |
11K |
3 |
13/10/20 |
13/10/20 |
ASX - By Stock
|
55
|
11K
|
3
|
|
ASX - By Stock
|
ACW |
Re:
could see .04
|
|
Ricksanchezc137
|
160 |
39K |
8 |
08/09/20 |
08/09/20 |
ASX - By Stock
|
160
|
39K
|
8
|
|
ASX - By Stock
|
ACW |
Re:
could see .04
|
|
Ricksanchezc137
|
160 |
39K |
1 |
27/08/20 |
27/08/20 |
ASX - By Stock
|
160
|
39K
|
1
|
|
ASX - By Stock
|
ACW |
Re:
could see .04
|
|
Ricksanchezc137
|
160 |
39K |
2 |
27/08/20 |
27/08/20 |
ASX - By Stock
|
160
|
39K
|
2
|
|
ASX - By Stock
|
ACW |
Re:
could see .04
|
|
Ricksanchezc137
|
160 |
39K |
0 |
26/08/20 |
26/08/20 |
ASX - By Stock
|
160
|
39K
|
0
|
|
ASX - By Stock
|
ACW |
Re:
could see .04
|
|
Ricksanchezc137
|
160 |
39K |
8 |
26/08/20 |
26/08/20 |
ASX - By Stock
|
160
|
39K
|
8
|
|
ASX - By Stock
|
ACW |
Re:
Ann: Quarterly Activity Report & Appendix 4C
|
|
Ricksanchezc137
|
19 |
4.2K |
14 |
29/07/20 |
29/07/20 |
ASX - By Stock
|
19
|
4.2K
|
14
|
|
ASX - By Stock
|
ACW |
Re:
could see .04
|
|
Ricksanchezc137
|
160 |
39K |
14 |
28/07/20 |
28/07/20 |
ASX - By Stock
|
160
|
39K
|
14
|
|
ASX - By Stock
|
ACW |
Re:
could see .04
|
|
Ricksanchezc137
|
160 |
39K |
4 |
23/07/20 |
23/07/20 |
ASX - By Stock
|
160
|
39K
|
4
|
|
ASX - By Stock
|
ACW |
Re:
Ann: Market Update and ACW to Participate in BIO Digital
|
|
Ricksanchezc137
|
108 |
30K |
3 |
18/06/20 |
18/06/20 |
ASX - By Stock
|
108
|
30K
|
3
|
|
ASX - By Stock
|
ACW |
Re:
Ann: Market Update and ACW to Participate in BIO Digital
|
|
Ricksanchezc137
|
108 |
30K |
2 |
16/06/20 |
16/06/20 |
ASX - By Stock
|
108
|
30K
|
2
|
|
ASX - By Stock
|
ACW |
Re:
Ann: Market Update and ACW to Participate in BIO Digital
|
|
Ricksanchezc137
|
108 |
30K |
11 |
16/06/20 |
16/06/20 |
ASX - By Stock
|
108
|
30K
|
11
|
|
ASX - By Stock
|
ACW |
Re:
11βHSD1 inhibitor use in human disease- a systematic review and narrative synthesis
|
|
Ricksanchezc137
|
80 |
28K |
11 |
04/06/20 |
04/06/20 |
ASX - By Stock
|
80
|
28K
|
11
|
|
ASX - By Stock
|
ACW |
Re:
11βHSD1 inhibitor use in human disease- a systematic review and narrative synthesis
|
|
Ricksanchezc137
|
80 |
28K |
3 |
02/06/20 |
02/06/20 |
ASX - By Stock
|
80
|
28K
|
3
|
|
ASX - By Stock
|
ACW |
Re:
11βHSD1 inhibitor use in human disease- a systematic review and narrative synthesis
|
|
Ricksanchezc137
|
80 |
28K |
3 |
27/05/20 |
27/05/20 |
ASX - By Stock
|
80
|
28K
|
3
|
|
ASX - By Stock
|
ACW |
Re:
11βHSD1 inhibitor use in human disease- a systematic review and narrative synthesis
|
|
Ricksanchezc137
|
80 |
28K |
26 |
10/05/20 |
10/05/20 |
ASX - By Stock
|
80
|
28K
|
26
|
|
ASX - By Stock
|
ACW |
Re:
11βHSD1 inhibitor use in human disease- a systematic review and narrative synthesis
|
|
Ricksanchezc137
|
80 |
28K |
16 |
07/05/20 |
07/05/20 |
ASX - By Stock
|
80
|
28K
|
16
|
|
ASX - By Stock
|
ACW |
Re:
11βHSD1 inhibitor use in human disease- a systematic review and narrative synthesis
|
|
Ricksanchezc137
|
80 |
28K |
3 |
07/05/20 |
07/05/20 |
ASX - By Stock
|
80
|
28K
|
3
|
|
ASX - By Stock
|
ACW |
Re:
Ann: Actinogen Presentation at AAT-ADPD International Congress
|
|
Ricksanchezc137
|
15 |
6.1K |
5 |
05/05/20 |
05/05/20 |
ASX - By Stock
|
15
|
6.1K
|
5
|
|
ASX - By Stock
|
ACW |
Re:
Ann: Actinogen Presentation at AAT-ADPD International Congress
|
|
Ricksanchezc137
|
15 |
6.1K |
8 |
04/05/20 |
04/05/20 |
ASX - By Stock
|
15
|
6.1K
|
8
|
|
ASX - By Stock
|
ACW |
Re:
Ann: Actinogen presents latest Xanamem data at AD Conference
|
|
Ricksanchezc137
|
68 |
26K |
0 |
08/04/20 |
08/04/20 |
ASX - By Stock
|
68
|
26K
|
0
|
|
ASX - By Stock
|
ACW |
Re:
Ann: Actinogen presents latest Xanamem data at AD Conference
|
|
Ricksanchezc137
|
68 |
26K |
1 |
06/04/20 |
06/04/20 |
ASX - By Stock
|
68
|
26K
|
1
|
|
ASX - By Stock
|
ACW |
Re:
Ann: Actinogen presents latest Xanamem data at AD Conference
|
|
Ricksanchezc137
|
68 |
26K |
2 |
06/04/20 |
06/04/20 |
ASX - By Stock
|
68
|
26K
|
2
|
|
ASX - By Stock
|
ACW |
Re:
Ann: Actinogen presents latest Xanamem data at AD Conference
|
|
Ricksanchezc137
|
68 |
26K |
3 |
06/04/20 |
06/04/20 |
ASX - By Stock
|
68
|
26K
|
3
|
|